Last updated on November 2017

A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.


Brief description of study

Study Description:
The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
Eligibility Criteria:
Between the ages of 60-75; Not experiencing memory loss; Have a study partner.
Other Details:
May be compensated for time and travel.

Clinical Study Identifier: TX154169

Contact Investigators or Research Sites near you

Start Over

Jennifer Cavin

NeuroStudies.net, LLC
Decatur, GA USA
  Connect »